Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus SDAMLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus SDAMLO.
REDEMPLO vs SDAMLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
Sdamlo is a combination of amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, and sodium salt, which is not a standard component; likely a typo for amlodipine alone or amlodipine/valsartan. Assuming amlodipine: inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced afterload.
100 mg orally once daily, with or without food.
Oral: 5-10 mg once daily, may be titrated up to a maximum of 20 mg once daily based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
Terminal elimination half-life is 30-50 hours (mean 40 h); allows once-daily dosing with steady state achieved after 7-10 days.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Primarily renal (80% as unchanged drug and inactive metabolites); 20% biliary/fecal.
Category C
Category C
Unknown
Unknown